68Ga PET/CT Imaging in Breast Cancer Patients

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Nov 14, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging method for breast cancer patients using a special substance called 68Ga-P16-093. This substance targets a protein found on cancer cells, which may help doctors detect and evaluate breast cancer more accurately. The trial will compare the effectiveness of this new imaging technique with a standard method called 18F-FDG.

To be eligible for this study, participants need to have breast cancer that has been confirmed by ultrasound or a biopsy. They should be willing to undergo both types of imaging tests within two weeks and provide written consent to participate. The trial is open to all adults aged 29 to 74. Participants can expect to receive two different imaging scans to help researchers understand how well the new method works. Importantly, individuals with an allergy to the imaging substance or certain medical conditions may not be able to join the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • breast cancer patients highly suggested by ultrasound or histologically confirmed;
• • 68Ga-P16-093 PET/CT and 18F-FDG within two weeks;
• • signed written consent.
• Exclusion Criteria:
• • known allergy against PSMA;
• • any medical condition that in the opinion of the investigator may significantly interfere with study compliance.